Meet Dr. Cheryl Rowe-Rendleman: A Trailblazer in Ophthalmic Research and Regulatory Consulting
In the fast-paced world of drug and device development, having a seasoned expert to navigate the complex regulatory landscape can make all the difference. Enter Dr. Cheryl Rowe-Rendleman, the CEO and managing consultant at OMAR Consulting Group, who has been at the forefront of regulatory and clinical consulting for nearly two decades.
A Legacy of Excellence
Since 2006, OMAR (Ophthalmic Management and Research) has been a beacon of expertise in the field, specializing in regulatory and clinical consulting for drugs and devices across the US, Europe, and China. Dr. Rowe-Rendleman, along with her team of five specialists, has played a pivotal role in developing successful regulatory strategies that guide research from the laboratory bench to the patient’s bedside and ultimately to market approval.
A Career Marked by Achievement
Dr. Rowe-Rendleman’s impressive career spans various high-profile positions, including:
- Senior Vice President and Head of Regulatory Affairs at Aviceda Therapeutics
- Consulting Vice President in charge of Device Strategic Development at Orbit Biomedical
- Clinical Director at Ono Pharma, USA
- Regulatory consultant in residence at several nonprofit and academic institutions
Her expertise is further evidenced by her personal involvement in directing or designing over 100 clinical trials for companies across the US, EU, and China. Dr. Rowe-Rendleman’s regular interactions with regulatory bodies such as the FDA, EMA, and PMDA underscore her global influence in the field.
A Career Marked by Achievement
Dr. Rowe-Rendleman’s impressive career spans various high-profile positions, including:
- Senior Vice President and Head of Regulatory Affairs at Aviceda Therapeutics
- Consulting Vice President in charge of Device Strategic Development at Orbit Biomedical
- Clinical Director at Ono Pharma, USA
- Regulatory consultant in residence at several nonprofit and academic institutions
Her expertise is further evidenced by her personal involvement in directing or designing over 100 clinical trials for companies across the US, EU, and China. Dr. Rowe-Rendleman’s regular interactions with regulatory bodies such as the FDA, EMA, and PMDA underscore her global influence in the field.
Leadership in Professional Organizations
Beyond her consulting work, Dr. Rowe-Rendleman is deeply involved in shaping the future of ophthalmic research:
- Steering committee member for The Forum for Collaborative Research (UC Berkeley)
- Member of the Association of Research in Vision and Ophthalmology
- Serves on the Board of Governors
- Member of the Bench to Bedside Steering Committee
- Member of the Women in Vision Research Committees
- Recently served as secretary of the Association for Ocular Pharmacology and Therapeutics (AOPT)
- Awarded the prestigious title of Fellow of AOPT
Educational Background and Innovation
Dr. Rowe-Rendleman’s journey to becoming a leader in her field began with an undergraduate degree from Princeton University, followed by a graduate degree from the University of Houston-Texas. Her postgraduate work included fellowships in neurobiology at the University of Texas Medical School and ophthalmology at the University of San Francisco Medical School.
Demonstrating her innovative spirit, Dr. Rowe-Rendleman has been named as an inventor on three patents in the field of drug delivery, further cementing her status as a pioneer in ophthalmic research and development.
As we look to the future of drug and device development, professionals like Dr. Cheryl Rowe-Rendleman continue to light the way, ensuring that groundbreaking treatments make their way safely and efficiently from concept to reality.